Eli Lilly Message Board - Msg: 32940760

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Eli Lilly

LLY 1,042

-1.2%

Dec 17 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Moonray	9/19/2020 1:11:23 PM
	of 642

COVID-19 treatment linked to B.C. biotech shows signs of reducing hospitalizations What happened: COVID-19 treatment developed in part by a Vancouver company is showing signs of reducing hospitalizations Why it matters: Federal government has allocated $175 million to AbCellera to develop therapeutic antibodies A COVID-19 treatment that emerged from a partnership between a B.C. biotech company and an American pharmaceutical giant is producing positive results in clinical trials. The pharmaceutical company reports the rate of hospitalizations and emergency room visits for those treated with the antibody known as LY-CoV555 was 1.7% compared with 6% for those treated with a placebo. Lilly said this represents a 72% risk reduction, while the treatment was “well-tolerated, with no drug-related serious adverse events reported” among those taking LY-CoV555. In May, Ottawa earmarked $175 million for AbCellera to pursue the development, manufacturing and distribution of therapeutic antibodies. More at: biv.com o~~~ O

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next